Neuromed-Merck

Neuromed/Merck & Co Neuromed is a privately held biopharmaceutical company committed to developing the next generation of chronic pain drugs targeted to specific calcium channels. 

Merck & Co., Inc. is a global research-driven pharmaceutical company.

Burrill & Company’s Role

The Merchant Banking Group advised Neuromed on:

• The choice of partner
• The appropriate deal structure and key terms
• The deal negotiation
• Senior decision-making at Merck
• The deal closing process

The transaction was closed in a tight window a few weeks before the receipt of phase II data

• $25M cash upfront and 2 years research funding
• $450M in milestones and a US co-promotion option